Lenacapavir: First Approval-Reference-Cited by-同舟云学术

Lenacapavir: First Approval

Published:2022-09 Issue:14 Volume:82 Page:1499-1504
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Paik Julia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-022-01786-0.pdf

Reference19 articles.

1. Teeraananchai S, Chaivooth S, Kerr SJ, et al. Life expectancy after initiation of combination antiretroviral therapy in Thailand. Antivir Ther. 2017;22(5):393–402.

2. Oh KS, Han E. A comparison of medication adherence and viral suppression in antiretroviral treatment-naive patients with HIV/AIDS depending on the drug formulary. PLoS ONE. 2021;16(1): e0245185.

3. Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11): e1002183.

4. Gilead Sciences Inc. Lenacapavir (Sunlenca®): EU summary of product characteristics. 2022. https://ema.europa.eu/. Accessed 21 Sep 2022.

5. Gilead Sciences Inc. Gilead announces first regulatory approval for Sunlenca® (lenacapavir), the only twice-yearly HIV treatment option [media release]. 22 Aug 2022. https://www.gilead.com/.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis;Medicinal Chemistry Research;2024-09-15

2. The Human T-cell Leukemia Virus capsid protein is a potential drug target;2024-09-10

3. Twice-yearly lenacapavir demonstrated exceptional efficacy for HIV prevention;The Innovation;2024-09

4. Viral Factors in Modulation of Host Immune Response: A Route to Novel Antiviral Agents and New Therapeutic Approaches;International Journal of Molecular Sciences;2024-08-29

5. Doravirine (Pifeltro): A Third‐Generation Non‐Nucleoside Reverse Transcriptase Inhibitor as a Treatment of HIV ‐1 Infection;Chemistry and Pharmacology of Drug Discovery;2024-08-16